Literature DB >> 20606282

Crystallization and preliminary X-ray analysis of the chemokine-binding protein from orf virus (Poxviridae).

Rafael Miguez Couñago1, Stephen B Fleming, Andrew A Mercer, Kurt L Krause.   

Abstract

The parapoxvirus orf virus (ORFV) encodes a chemokine-binding protein (CBP) that functions to downregulate the host's immune response at the site of infection by blocking the chemokine-induced recruitment of immune cells. In order to shed light on the structural determinants of CBP-chemokine binding, ORFV CBP was crystallized as part of an ongoing structure-function study on this protein. ORFV CBP crystals were obtained by the sitting-drop vapour-diffusion technique using ammonium citrate as a precipitant. The crystal quality was greatly improved through the addition of small-molecule additives to the crystallization mother liquor. ORFV CBP crystals diffracted X-rays to 2.50 A resolution and belonged to the hexagonal space group P6(1)22 or its enantiomorph P6(5)22, with unit-cell parameters a = b = 75.62, c = 282.49 A, alpha = 90, beta = 90, gamma = 120 degrees.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606282      PMCID: PMC2898470          DOI: 10.1107/S1744309110018166

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  30 in total

Review 1.  Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins.

Authors:  Elaine K Lau; Samantha Allen; Andro R Hsu; Tracy M Handel
Journal:  Adv Protein Chem       Date:  2004

2.  Transient expression and purification of chimeric heavy chain antibodies.

Authors:  Jianbing Zhang; Xin Liu; Andrea Bell; Rebecca To; Toya Nath Baral; Ali Azizi; Jianjun Li; Brian Cass; Yves Durocher
Journal:  Protein Expr Purif       Date:  2008-10-26       Impact factor: 1.650

3.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

Review 4.  The molecular biology of leukocyte chemoattractant receptors.

Authors:  P M Murphy
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta.

Authors:  Li Zhang; Michele Derider; Melissa A McCornack; Shu-Chuan Jao; Nancy Isern; Traci Ness; Richard Moyer; Patricia J LiWang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

6.  Removal of salt from a salt-induced protein crystal without cross-linking. Preliminary examination of "desalted" crystals of phosphoglucomutase by X-ray crystallography at low temperature.

Authors:  W J Ray; J T Bolin; J M Puvathingal; W Minor; Y W Liu; S W Muchmore
Journal:  Biochemistry       Date:  1991-07-16       Impact factor: 3.162

7.  Glycosaminoglycans mediate cell surface oligomerization of chemokines.

Authors:  A J Hoogewerf; G S Kuschert; A E Proudfoot; F Borlat; I Clark-Lewis; C A Power; T N Wells
Journal:  Biochemistry       Date:  1997-11-04       Impact factor: 3.162

8.  Protein production by auto-induction in high density shaking cultures.

Authors:  F William Studier
Journal:  Protein Expr Purif       Date:  2005-05       Impact factor: 1.650

Review 9.  Role of chemokines in endocrine autoimmune diseases.

Authors:  Mario Rotondi; Luca Chiovato; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  Endocr Rev       Date:  2007-05-02       Impact factor: 19.871

10.  Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors.

Authors:  Bruce T Seet; Catherine A McCaughan; Tracy M Handel; Andrew Mercer; Craig Brunetti; Grant McFadden; Stephen B Fleming
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more
  1 in total

1.  Optimisation of Neuraminidase Expression for Use in Drug Discovery by Using HEK293-6E Cells.

Authors:  Ashley C Campbell; John J Tanner; Kurt L Krause
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.